Dive into the latest episode of Pharmacy Friends for a discussion of the FDA Commissioner’s National Priority Voucher pilot. While accelerated approvals may improve access to innovative therapies, what could a compressed decision-making window mean for evidence review, affordability assessment and implementation planning?

Prime experts Angela Sutton and Bob Greer explore the important roles clinical confidence and operational readiness will play in making solid coverage decisions. Hear what they’re most focused on, including:

• Managing drug spend
• Assessing coverage strategies
• Determining policy risk

00:00 Introduction

02:10 What's generating all the questions now?

04:35 FDA Hearing

05:50 Pro's and con's of accelerated drug approvals

11:05 Policy uncertainty and impact to payers

11:54 Impact of FDA leadership changes

12:24 Meeting the moment

15:26 Using data to make better decisions that need to be fast

18:39 What we would tell the acting FDA leadership that matters

23:15 Closing